Innervate Radiopharmaceuticals is a startup based in the United States.
Based in the United States, Innervate Radiopharmaceuticals is a startup.
Innervate Radiopharmaceuticals develops PET imaging and therapeutic radiopharmaceuticals, with a lead asset 18F-metafluorobenzylguanidine (mFBG) aimed at improving detection and management of neuroblastoma. The company is conducting a pivotal Phase III clinical trial in neuroblastoma patients and a Phase I/IIa study evaluating mFBG for myocardial sympathetic innervation.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.